Drug Update logo on top of pills (green)

Drug Update: August 2017

New Specialty Drug Approvals FDA Approves New Hepatitis C Medication: Mavyret® Hepatitis C is a viral disease that causes inflammation of the liver, which can lead to decreased liver function and in some cases liver failure. According to the Centers for Disease Control and Prevention (CDC), an estimated 2.7 to 3.9 million people in the […]

Drug Update logo on top of pills (orange)

Drug Update: July 2017

New Specialty Drug Approvals FDA Approves New Hepatitis C Medication: Vosevi® In July 2017, the U.S. Food & Drug Administration (FDA) approved a new fixed-dose combination medication for the treatment of chronic hepatitis C virus (HCV): Vosevi®. Vosevi is a combination of three anti-viral medications: sofosbuvir, velpatasvir, voxilaprevir. Vosevi is approved for the treatment of […]

Drug Update logo on top of pills (purple)

Drug Update: June 2017

New Specialty Drug Approvals FDA Approves New Biologic for Rheumatoid Arthritis In May of 2017, the U.S. Food & Drug Administration (FDA) approved a new medication, Kevzara® (sarilumab), for the treatment of moderately to severely active rheumatoid arthritis (RA). Kevzara is indicated specifically for adults who have had an inadequate response or intolerance to one […]

Drug Update logo on top of pills (gold)

Drug Update: May 2017

New Drug Approvals FDA Approves New Drug for Rare, Progressive Nerve Disease Earlier this month, the U.S. Food & Drug Administration (FDA) approved a new medication, Radicava® (edaravone), for the treatment of patients with amytrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. ALS is a rare progressive disease affecting nerve cells used for […]

Drug Update logo on top of pills (orange)

Drug Update: April 2017

New Drug Approvals New Biologic Approved for Plaque Psoriasis The U.S. Food and Drug Administration (FDA) recently approved a new monoclonal antibody, Siliq® (brodalumab), for the treatment of adults with moderate-to-severe plaque psoriasis. It is indicated specifically for patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost […]

Drug Update logo on top of pills (purple)

Drug Update: March 2017 Issue 1

New Drug Launches FDA Approves First Drug for Rare Skin Cancer Last week, the U.S. Food and Drug Administration approved the first treatment, Bavencio® (avelumab), for Merkel cell carcinoma (MCC). Bavencio received accelerated approval for adults and pediatric patients 12 years and older with metastatic MCC, including for patients who have not received prior chemotherapy. […]

Drug Update logo on top of pills (green)

Drug Update: February 2017 Issue 1

New Drug Launches FDA Approves Emflaza® for Duchenne Muscular Dystrophy In February 2017, the U.S. Food and Drug Administration (FDA) approved Emflaza® (deflazacort) for the treatment of patients 5 years and older with Duchenne Muscular Dystrophy (DMD). DMD is a rare, genetic condition resulting in progressive muscle weakness. Emflaza is the second drug to receive […]

Drug Update logo on top of pills (gold)

Drug Update: January 2017 Issue 2

Specialty Drug News New Review Date for Rheumatoid Arthritis Drug Last week the manufacturer of baricitinib, a new therapy for rheumatoid arthritis, announced the U.S. Food & Drug Administration (FDA) has extended the review period for the investigational agent by 3 months. A decision regarding approval of baricitinib was previously expected by January 19, 2017. […]